Uncategorized
Aerie Pharmaceuticals reports third quarter loss of $23.8 million
Aerie Pharmaceuticals reported a net loss of $23.8 million, or $0.81 per share, in the third quarter, compared with a net loss of $18 million, or $0.69 per share, in the third quarter of 2015.A company press release attributed $23.3 million of the loss to operating expenses: $12.7 million in research and development expenses and $10.6 million in general and administrative expenses.